Related Experiment Videos
HLA alloimmunization in patients requiring ventricular assist device support
David H McKenna1, Ted Eastlund, Miriam Segall
1Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA. mcken020@umn.edu
Summary
Ventricular assist device (VAD) patients developing human leukocyte antigen (HLA) antibodies may be linked to extensive blood transfusions, not the VAD itself. Reducing transfusions and using leukoreduction may lower alloimmunization rates.
Area of Science:
- Immunology
- Cardiology
- Transplantation
Background:
- Ventricular assist devices (VADs) are crucial for heart failure patients awaiting transplantation.
- VAD use has been linked to human leukocyte antigen (HLA) antibody development, potentially due to immune activation by the device.
- This study investigated HLA antibody formation in VAD patients to identify rates and causes.
Purpose of the Study:
- To determine the incidence of HLA antibody formation in patients supported by VADs.
- To explore potential causes of HLA antibody development during VAD support.
Main Methods:
- Retrospective review of 29 VAD patients without pre-existing HLA antibodies (1995-2000).
- Analysis of clinical history, transfusion records, and HLA antibody testing.
- HLA antibody testing utilized anti-globulin-augmented cytotoxicity or ELISA kits.
Main Results:
- 28% (8 of 29) of patients developed HLA antibodies post-VAD implantation.
- Patients with HLA antibodies received significantly more transfusions (99 vs. 34).
- No significant correlation found between HLA antibody formation and patient demographics, heart failure etiology, prior surgery, or VAD duration.
Conclusions:
- Extensive blood transfusion appears to be a primary driver of HLA alloimmunization in VAD patients.
- The observed rate of HLA alloimmunization is comparable to other multi-transfused patient groups.
- Leukoreduction and other strategies are recommended to mitigate alloimmunization and improve transplant outcomes.